Today: 21 July 2026
Browse Category

Pharmaceuticals 27 April 2026 - 11 May 2026

Hims & Hers Health Earnings Today: Why One GLP-1 Question Could Move HIMS Stock

Hims & Hers Health Earnings Today: Why One GLP-1 Question Could Move HIMS Stock

Investors eye Hims & Hers Health Inc. as it approaches Monday’s first-quarter results, with attention locked on the future of its weight-loss segment—especially after the company pulled back from widely promoted compounded GLP-1 drugs. Earnings will post after the U.S. markets close, followed by a 5 p.m. ET conference call, according to Hims & Hers.
11 May 2026
····
Pfizer Stock Faces a Fresh COVID Patent Overhang as Investors Wait for Its Next Growth Act

Pfizer Stock Faces a Fresh COVID Patent Overhang as Investors Wait for Its Next Growth Act

Acuitas Therapeutics has failed in its attempt to shield Pfizer Inc. and BioNTech’s Comirnaty COVID-19 vaccine from GSK’s patent claims, after a Delaware federal judge tossed the case. Judge Gregory Williams sided with GSK’s subsidiaries, dismissing the Acuitas action for lack of subject-matter jurisdiction. In effect, the court said it didn’t have the authority to hear the suit as filed, leaving the broader patent dispute over the high-profile vaccine unresolved.
11 May 2026
··
Traws Pharma Stock Jumps As Biotech Targets Hantavirus After Cruise Ship Deaths

Traws Pharma Stock Jumps As Biotech Targets Hantavirus After Cruise Ship Deaths

Traws Pharma Inc. on Friday announced plans to push ahead with possible clinical candidates targeting hantavirus infections, shifting the antiviral developer’s focus after a lethal outbreak on a cruise ship. The company hasn’t disclosed a frontrunner. Chief Scientific Officer C. David Pauza said Traws “plans to rapidly advance clinical candidates.” Chief Medical Officer Robert R. Redfield described the move as an emergency push for “life-saving treatments.”
8 May 2026
···
Pfizer Earnings Beat Wall Street, But The Patent Cliff Is Still The Story

Pfizer Earnings Beat Wall Street, But The Patent Cliff Is Still The Story

Pfizer turned in a first-quarter profit that beat forecasts on Tuesday, thanks in large part to solid demand for established drugs like the blood thinner Eliquis and cancer therapy Padcev, cushioning the impact of another steep fall in sales of its COVID offerings. Adjusted earnings landed at 75 cents per share, with revenue reaching $14.45 billion—both topping Wall Street’s consensus for 72 cents per share and $13.79 billion in revenue, according to Reuters.
5 May 2026
···
Mirum Stock Jumps After Volixibat Trial Win Puts First PSC Itch Drug Within Reach

Mirum Stock Jumps After Volixibat Trial Win Puts First PSC Itch Drug Within Reach

Shares of Mirum Pharmaceuticals surged Monday, after the company announced its experimental therapy volixibat hit the primary endpoint in a Phase 2b study targeting primary sclerosing cholangitis, or PSC—a rare liver condition marked by scarring of the bile ducts and potential liver failure. The study zeroed in on cholestatic pruritus, the intense itching caused by impaired bile flow and notorious as one of PSC’s toughest symptoms.
4 May 2026
··
Recursion Pharmaceuticals Stock: Founder Chris Gibson to Leave Board as RXRX Nears Q1 Earnings

Recursion Pharmaceuticals Stock: Founder Chris Gibson to Leave Board as RXRX Nears Q1 Earnings

Recursion Pharmaceuticals announced that founder and board chair Chris Gibson won’t seek re-election at this year’s annual meeting, marking another step back from direct oversight after he exited the chief executive role a few months ago. CEO Najat Khan insisted the company stays committed to “continuity and long-term value creation.” Gibson described his time building Recursion as “one of the most rewarding journeys.”
1 May 2026
··
Moderna Revenue Beat: Overseas Covid Shot Sales Jump, but $900 Million Charge Clouds the Turnaround

Moderna Revenue Beat: Overseas Covid Shot Sales Jump, but $900 Million Charge Clouds the Turnaround

Moderna Inc. topped first-quarter revenue forecasts Friday, with international Covid-19 vaccine sales outpacing what the U.S. market delivered—setting the biotech up for a stronger 2026 kickoff than many investors had penciled in. Revenue hit $389 million, a jump from $108 million the previous year, and of that, $311 million was generated outside the U.S.)
1 May 2026
·
Teva Stock Jumps As Branded Drugs Start Carrying The Old Generics Giant

Teva Stock Jumps As Branded Drugs Start Carrying The Old Generics Giant

Teva Pharmaceutical Industries shares rallied in New York on Wednesday, with the Israeli drugmaker topping first-quarter profit forecasts. Results benefited from a quicker pivot to branded drugs and reduced exposure to lower-margin generics. For investors, it’s a more direct look at Chief Executive Richard Francis’s turnaround efforts—showing more than another quarter of trimming expenses.
29 April 2026
··
1 … 3 4 5 6 7 … 44
Go toTop